RxDoctor Payments Data

Freij Gobal, MD

Interventional Cardiology · Gig Harbor, WANPI 1073587614

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (44.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Abbott at 44.4% of the total. Reporting peaked in 2020 at $2,408 and has fallen 77.9% since, to $532 in 2025.

$5,546in general payments, 2019–2025

Across 51 payments — averaging $108.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Siemens Medical Solutions USA, Inc.$1K
  • Medtronic$853
  • Astellas Pharma US Inc$354
  • Inari Medical, Inc.$152
  • Penumbra, Inc.$145
  • plus $437 from 6 others

What the payments were for

  • Consulting fees$1,14021%
  • Travel & lodging$2,47745%
  • Food & beverage$1,57528%
  • Education$3546%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,546 in reported general payments places this provider in the 55th percentile of 125 interventional cardiology providers in Washington.

See all interventional cardiology providers in Washington

Medicare billing

Part B allowed, 2024
$272,769
Medicare patients
1,326
Services billed
3,108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban113$130,284
EliquisApixaban65$99,585
EntrestoSacubitril/Valsartan30$43,084
JardianceEmpagliflozin13$12,483
Repatha SureclickEvolocumab13$8,214
Metoprolol Succinate209$2,939
Atorvastatin Calcium157$1,452
Losartan Potassium103$1,318
Amlodipine Besylate94$1,039
Carvedilol119$910
Diltiazem 24hr Er (Cd)Diltiazem Hcl24$773
Amiodarone Hcl21$750
ClopidogrelClopidogrel Bisulfate114$741
Spironolactone70$705
Furosemide93$508

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$26$43,08430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 125 interventional cardiology providers in Washington.

Other interventional cardiology in Gig Harbor

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →